The Latest Breaking News from Biogen

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

Upgrades

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

TAMPA, Fla. -- At 53, Michele Hall was at the height of her legal career. She’d just sent her three kids to college. She had decades ahead with her husband Doug — after nearly 30 years of marriage, the couple looked forward to celebrating 30 more.